Stay updated on Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page
- Check5 days agoChange DetectedA new revision label v3.7.0 was added to the record history, replacing the previous v3.6.6 entry.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedA new revision entry, v3.6.6, was added to the history; the previous revision, v3.6.5, has been removed from the history.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision: v3.6.5 has been added to the page history, replacing the previous v3.6.4. This represents a metadata update to the page rather than any substantive changes to study information.SummaryDifference0.0%

- Check63 days agoChange DetectedThe history section now shows Revision: v3.6.4, replacing Revision: v3.6.3, reflecting a new version of the study record history.SummaryDifference0.0%

- Check84 days agoChange DetectedThe study history now shows the latest Revision: v3.6.3, replacing the previous Revision: v3.6.0.SummaryDifference0.0%

- Check98 days agoChange DetectedThe study record now shows recruitment is closed, indicating enrollment has ended. The revision history is updated with a new 'Revision: v3.6.0' entry and the previous 'Revision: v3.5.5' entry is removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.